Mf — Manufacturing
Advanced regenerative therapies require highly standardized and tightly controlled manufacturing processes. From donor qualification and cell banking to expansion, cryopreservation, and release testing, every production stage is performed under stringent GMP-oriented quality standards to ensure safety, sterility, consistency, and biological integrity. Full traceability is maintained throughout the entire manufacturing chain — from donor selection and raw materials to final product release — supporting transparency, reproducibility, and regulatory compliance. Validated manufacturing workflows include environmental monitoring, in-process controls, identity and viability testing, microbiological quality assessment, and standardized release criteria. Strict control of culture conditions, passage number, cryopreservation protocols, and transport logistics is essential for preserving the biological functionality and reproducibility of regenerative products intended for clinical application. References: EMA Guidelines for ATMPs; Sensebé & Gadelorge, 2021; EMA/CAT Reflection Paper, 2018.
Date:
2022-11-09
Category: